Literature DB >> 31147187

Effects of a fully magnetically levitated centrifugal-flow or axial-flow left ventricular assist device on von Willebrand factor: A prospective multicenter clinical trial.

Aditya Bansal1, Nir Uriel2, Paolo C Colombo3, Keerthy Narisetty4, James W Long5, Arvind Bhimaraj6, Joseph C Cleveland7, Daniel J Goldstein8, John M Stulak9, Samer S Najjar10, David E Lanfear11, Eric D Adler12, Walter P Dembitsky13, Sami I Somo14, Daniel L Crandall14, Dong Chen9, Jean Marie Connors15, Mandeep R Mehra16.   

Abstract

BACKGROUND: Increased shear stress conferred upon the circulation by continuous-flow pumps is associated with hemocompatibility-related adverse events, principally bleeding within the gastrointestinal system, and linked to the degradation of high-molecular-weight multimers (HMWMs) of von Willebrand factor (vWF). We evaluated the structure and functional characteristics of vWF HMWMs in patients with the fully magnetically levitated centrifugal-flow HeartMate 3 (HM3) and the continuous axial-flow HeartMate II (HMII) pump. Findings were correlated with bleeding events.
METHODS: In a prospective, multicenter, comparative cohort study, 60 patients from the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 Continued Access Protocol (NCT02892955) with an HM3 pump were compared with 30 randomly selected HMII patients from the PREVENtion of HeartMate II Pump Thrombosis study (NCT02158403) biobank. The primary end point was the difference in the normalized vWF HMWM ratio (ratio of the HMWMs to the intermediate- and low-molecular-weight multimers, normalized to pooled plasma from healthy volunteers) between the HM3 and the HMII pump at 90 days after implantation. Assay tests for vWF activity, vWF antigen, vWF activity to antigen ratio, coagulation factor VIII activity, and ADAMTS13 activity were measured by using standard protocols. Differences in these markers were compared in the context of clinical characteristics and correlated with adjudicated bleeding events within the HM3 group.
RESULTS: Of 51 and 29 evaluable patients in the HM3 and HMII arms, respectively, those implanted with the HM3 pump exhibited greater preservation of the vWF HMWM ratio than those with the HMII pump at 90 days after implantation (54.1% vs 42.4%, p < 0.0001). Laboratory values for all vWF assays (antigen, activity, and coagulation factor VIII activity) remained within the normal functional range with no significant differences observed between the pumps at 90 days after implantation. At baseline, there was a decrease in the structural integrity of vWF HMWMs that correlated with increasing heart failure severity as measured by the Interagency Registry for Mechanically Assisted Circulatory Support profile. Multivariable modeling identified the HM3 pump as the only independent variable that determined post-implantation preservation of the structural integrity of vWF HMWMs.
CONCLUSIONS: This prospective, multicenter comparative analysis study demonstrates that the fully magnetically levitated centrifugal-flow HM3 left ventricular assist device is associated with greater preservation of the structure of vWF HMWMs than the HMII mechanical bearing axial-flow pump.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HeartMate 3; advanced heart failure; bleeding; left ventricular assist device; von Willebrand factor

Year:  2019        PMID: 31147187     DOI: 10.1016/j.healun.2019.05.006

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  11 in total

1.  Bleeding in critical care associated with left ventricular assist devices: pathophysiology, symptoms, and management.

Authors:  F W G Leebeek; R Muslem
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

2.  Oncostatin M: a Potential Biomarker to Predict Infection in Patients with Left Ventricular Assist Devices.

Authors:  Hendra Setiadi; Ahmed M El-Banayosy; Susan George; David W Schmidtke; Aly El-Banayosy; Douglas A Horstmanshof; James W Long
Journal:  ASAIO J       Date:  2021-11-10       Impact factor: 3.826

Review 3.  Antithrombotic therapy for durable left ventricular assist devices - current strategies and future directions.

Authors:  Noah Weingarten; Cindy Song; Amit Iyengar; David Alan Herbst; Mark Helmers; Danika Meldrum; Sara Guevara-Plunkett; Jessica Dominic; Pavan Atluri
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2022-09-21

4.  Dynamic Forecasts of Survival for Patients Living With Destination Left Ventricular Assist Devices: Insights From INTERMACS.

Authors:  Katherine C Michelis; Lin Zhong; Matthias Peltz; Ambarish Pandey; W H Wilson Tang; Anand Rohatgi; James B Young; Mark H Drazner; Justin L Grodin
Journal:  J Am Heart Assoc       Date:  2020-07-10       Impact factor: 5.501

5.  Hemolysis induced by Left Ventricular Assist Device is associated with proximal tubulopathy.

Authors:  Tristan de Nattes; Pierre-Yves Litzler; Arnaud Gay; Catherine Nafeh-Bizet; Arnaud François; Dominique Guerrot
Journal:  PLoS One       Date:  2020-11-30       Impact factor: 3.240

6.  Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist device-supported patients for the non-left ventricular assist device specialist healthcare provider: Part 2: at the emergency department.

Authors:  Davor Milicic; Binyamin Ben Avraham; Ovidiu Chioncel; Yaron D Barac; Eva Goncalvesova; Avishai Grupper; Johann Altenberger; Maria Frigeiro; Arsen Ristic; Nicolaas De Jonge; Steven Tsui; Jacob Lavee; Giuseppe Rosano; Marisa Generosa Crespo-Leiro; Andrew J S Coats; Petar Seferovic; Frank Ruschitzka; Marco Metra; Stefan Anker; Gerasimos Filippatos; Stamatis Adamopoulos; Miriam Abuhazira; Jeremy Elliston; Israel Gotsman; Righab Hamdan; Yoav Hammer; Tal Hasin; Lorrena Hill; Osnat Itzhaki Ben Zadok; Wilfried Mullens; Sanemn Nalbantgil; Massimo Francesco Piepoli; Piotr Ponikowski; Luciano Potena; Arjang Ruhparwar; Aviv Shaul; Laurens F Tops; Stephan Winnik; Tiny Jaarsma; Finn Gustafsson; Tuvia Ben Gal
Journal:  ESC Heart Fail       Date:  2021-09-14

7.  Role of acquired von Willebrand syndrome in the development of bleeding complications in patients treated with Impella RP devices.

Authors:  Mehmet Oezkur; Sara Reda; Heiko Rühl; Nils Theuerkauf; Stefan Kreyer; Georg Daniel Duerr; Efstratios Charitos; Miriam Silaschi; Marta Medina; Sebastian Zimmer; Christian Putensen; Hendrik Treede
Journal:  Sci Rep       Date:  2021-12-09       Impact factor: 4.379

Review 8.  Cardiac Surgery in Advanced Heart Failure.

Authors:  Roger Hullin; Philippe Meyer; Patrick Yerly; Matthias Kirsch
Journal:  J Clin Med       Date:  2022-01-31       Impact factor: 4.241

Review 9.  New Developments in Diagnosis and Management of Acquired Hemophilia and Acquired von Willebrand Syndrome.

Authors:  Frank W G Leebeek
Journal:  Hemasphere       Date:  2021-06-01

10.  Adverse events with HeartMate-3 Left ventricular assist device: Results from the Manufacturer and User Facility Device Experience (MAUDE) database.

Authors:  Joseph N Heaton; Sohrab Singh; Matthew Li; Saraschandra Vallabhajosyula
Journal:  Indian Heart J       Date:  2021-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.